Daniel Correia
Directeur/Membre du Conseil chez Lymphact - Lymphocyte Activation Technologies SA
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Diogo Remechido | M | - |
Lymphact - Lymphocyte Activation Technologies SA
Lymphact - Lymphocyte Activation Technologies SA BiotechnologyHealth Technology Lymphact - Lymphocyte Activation Technologies SA provides biotechnology solutions. It develops treatments for cancer and chronic viral diseases. The firm offers a technology platform that generates autologous and heterologous cellular immune therapies for clinical applications. The company was founded by Diogo Remechido in 2013 and is headquartered in Lisbon, Portugal. | - |
Martinho Tojo | M | - |
Lymphact - Lymphocyte Activation Technologies SA
Lymphact - Lymphocyte Activation Technologies SA BiotechnologyHealth Technology Lymphact - Lymphocyte Activation Technologies SA provides biotechnology solutions. It develops treatments for cancer and chronic viral diseases. The firm offers a technology platform that generates autologous and heterologous cellular immune therapies for clinical applications. The company was founded by Diogo Remechido in 2013 and is headquartered in Lisbon, Portugal. | - |
David Zeferino D'Azevedo Cristina | M | - |
Lymphact - Lymphocyte Activation Technologies SA
Lymphact - Lymphocyte Activation Technologies SA BiotechnologyHealth Technology Lymphact - Lymphocyte Activation Technologies SA provides biotechnology solutions. It develops treatments for cancer and chronic viral diseases. The firm offers a technology platform that generates autologous and heterologous cellular immune therapies for clinical applications. The company was founded by Diogo Remechido in 2013 and is headquartered in Lisbon, Portugal. | - |
Bruno Silva-Santos | M | - |
Lymphact - Lymphocyte Activation Technologies SA
Lymphact - Lymphocyte Activation Technologies SA BiotechnologyHealth Technology Lymphact - Lymphocyte Activation Technologies SA provides biotechnology solutions. It develops treatments for cancer and chronic viral diseases. The firm offers a technology platform that generates autologous and heterologous cellular immune therapies for clinical applications. The company was founded by Diogo Remechido in 2013 and is headquartered in Lisbon, Portugal. | - |
Julie Dechanet-Merville | F | - |
Lymphact - Lymphocyte Activation Technologies SA
Lymphact - Lymphocyte Activation Technologies SA BiotechnologyHealth Technology Lymphact - Lymphocyte Activation Technologies SA provides biotechnology solutions. It develops treatments for cancer and chronic viral diseases. The firm offers a technology platform that generates autologous and heterologous cellular immune therapies for clinical applications. The company was founded by Diogo Remechido in 2013 and is headquartered in Lisbon, Portugal. | - |
Domenico Mavilio | M | - |
Lymphact - Lymphocyte Activation Technologies SA
Lymphact - Lymphocyte Activation Technologies SA BiotechnologyHealth Technology Lymphact - Lymphocyte Activation Technologies SA provides biotechnology solutions. It develops treatments for cancer and chronic viral diseases. The firm offers a technology platform that generates autologous and heterologous cellular immune therapies for clinical applications. The company was founded by Diogo Remechido in 2013 and is headquartered in Lisbon, Portugal. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Statistiques
Pays | Relations | % du total |
---|---|---|
Portugal | 6 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Daniel Correia
- Réseau Personnel